Anti SARS-CoV-2 Spike RBD Nanobody mAb (Clone A1)

CUSABIO

Catalog No.:
CSB-RA33245A2GMY-50
<strong>Activity Assay- ELISA</strong><br />The Binding Activity of SARS-CoV-2 Spike RBD Nanobody with SARS-CoV-2-S1-RBD<br />Activity: Measured by its binding ability in a functional ELISA. Immobilized SARS-CoV-2-S1-RBD (<a href='https://www.cusabio.com/Recombinant-Protein/Recombinant-Human-Novel-Coronavirus-Spike-glycoprotein-S---partial-12928552.html'>CSB-YP3324GMY1</a>) at 2 &mu;g/ml can bind SARS-CoV-2 Spike RBD Nanobody, the EC<sub>50</sub>&nbsp;is 0.8674 ng/ml.
<strong>GICA</strong><br />In the Colloidal Gold Immunochromatography Assay detection system, the background of antibody (CSB-RA33245A2GMY) is clean, the detection limit can be as low as 25ng/ml (1.75ng/0.07ml), and the sensitivity is very good.
SARS-CoV-2 Spike RBD Nanobody (CSB-RA33245A2GMY) competed with ACE2-HRP conjugate (<a href='https://www.cusabio.com/Other/Recombinant-Human-Angiotensin-converting-enzyme-2-ACE2--partial-12928566.html'>CSB-MP866317HU</a>) for binding to SARS-CoV-2-S1-RBD (<a href='https://www.cusabio.com/Recombinant-Protein/Recombinant-Human-Novel-Coronavirus-Spike-glycoprotein-S---partial-12928552.html'>CSB-YP3324GMY1</a>). The binding signal of SARS-CoV-2-S1-RBD and ACE2-HRP conjugate was gradually reduced as the SARS-CoV-2 Spike RBD Nanobody concentrations increased. It indicated that this SARS-CoV-2 Spike RBD Nanobody effectively inhibited the SARS-CoV-2-S1-RBD/ACE2 binding. And the IC<sub>50</sub> of this SARS-CoV-2 Spike RBD Nanobody is 1.296 nM.
SARS-CoV-2 Spike RBD Nanobody (CSB-RA33245A2GMY) competitively prevented SARS-CoV-2-S1-RBD (<a href='https://www.cusabio.com/Recombinant-Protein/Recombinant-Human-Novel-Coronavirus-Spike-glycoprotein-S---partial-12928552.html'>CSB-YP3324GMY1</a>) from binding to ACE2-HRP conjugate (<a href='https://www.cusabio.com/Other/Recombinant-Human-Angiotensin-converting-enzyme-2-ACE2--partial-12928566.html'>CSB-MP866317HU</a>). The inhibition efficacy of the SARS-CoV-2-S1-RBD/ACE2 binding was positively proportionally to the SARS-CoV-2 Spike RBD Nanobody concentrations. It showed that this SARS-CoV-2 Spike RBD Nanobody effectively inhibited the SARS-CoV-2-S1-RBD/ACE2 binding. And the IC<sub>50</sub> of this SARS-CoV-2 Spike RBD Nanobody is 0.1074 &mu;g/ml.
Shipping:
Calculated at Checkout
$441.00
Adding to cart… The item has been added
Recombinant anti-SARS-CoV-2 spike VHH is expressed from 293 cells (HEK293) with a human IgG1 Fc tag on C-terminal.

Product Specifications
Application ELISA, GICA
Reactivity Human, SARS Caronavirus
Clonality Monoclonal (Clone No.: A1)

Documents & Links for Anti SARS-CoV-2 Spike RBD Nanobody mAb (Clone A1)
Datasheet Anti SARS-CoV-2 Spike RBD Nanobody mAb (Clone A1) Datasheet

Documents & Links for Anti SARS-CoV-2 Spike RBD Nanobody mAb (Clone A1)
Datasheet Anti SARS-CoV-2 Spike RBD Nanobody mAb (Clone A1) Datasheet
!